Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms REDEEM
- Sponsors GlaxoSmithKline; GSK
- 19 May 2011 Results presented at the 106th Annual Meeting of the American Urological Association.
- 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
- 19 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.